U.S. Vasopressin Market Size And Forecast 2033

Growing Clinical Adoption and Advancements in Vasopressin Formulations to Drive U.S. Vasopressin Market to USD 4,657.5 Mn by 2033 at 14.7% CAGR – Coherent Market Insights

U.S. Vasopressin Market – Driver

High Burden of Sepsis and Septic Shock

The substantial number of patients requiring emergency treatment for sepsis and associated circulatory shock is driving demand for intravenous vasopressin in U.S. critical-care settings. In March 2026, the CDC reported that at least 1.7 million U.S. adults develop sepsis annually, while at least 350,000 die during hospitalization or are discharged to hospice. This large patient burden supports continued vasopressor consumption in hospitals and ICUs. (Source: CDC)

U.S. Vasopressin Market – Opportunity

Expansion of Generic and Premixed Products

Increasing regulatory access for generic and ready-to-administer vasopressin products creates opportunities for manufacturers to improve affordability, supply availability and hospital convenience. In May 2026, the FDA approved Sandoz’s ANDA for Vasopressin Injection USP, 200 units/10 mL, and confirmed its eligibility for 180-day generic exclusivity. In July 2026, the FDA also permitted future ANDAs referencing a 50-unit/50-mL premixed formulation, subject to regulatory requirements. (Source: U.S.FDA)

U.S. Vasopressin Market – Trends

Protocol-Based Use as an Add-On Vasopressor

Vasopressin is increasingly being incorporated into standardized septic-shock protocols as an adjunct rather than a first-line treatment. In March 2026, the Surviving Sepsis Campaign recommended adding vasopressin when norepinephrine requirements escalate, supporting its structured use in hospital intensive-care units.

Growing Research on Earlier Vasopressin Initiation

Clinical research is increasingly evaluating whether initiating vasopressin earlier can improve septic-shock outcomes and reduce catecholamine exposure. In 2026, the U.S. VASSPR trial compared initiation at lower versus higher norepinephrine-equivalent thresholds across 13 hospitals in Utah and Idaho, reflecting growing interest in treatment-timing optimization.

Shift Toward Ready-to-Use Premixed Formulations

Hospitals are increasingly adopting premixed vasopressin products to reduce preparation time, dilution errors and pharmacy workload. The DailyMed label updated on April 21, 2026, listed ready-to-use dextrose formulations containing 20, 40 and 60 units per 100 mL and 50 units per 50 mL.

Increasing Generic Competition

The U.S. vasopressin market is witnessing greater generic entry, which can expand product availability and place downward pressure on acquisition costs. On May 6, 2026, the FDA approved Sandoz’s 200-units/10-mL multiple-dose vasopressin vial and confirmed eligibility for 180-day generic exclusivity.

U.S. Vasopressin Market, by Type (Intravenous Injection, Intramuscular Injection, Subcutaneous Injection, and Others), by Application (Anti-diuretic Hormone Deficiency, Gastrointestinal Bleeding, Vasodilatory Shock, Ventricular Tachycardia, and Fibrillation), and by End User (Hospitals, Dental Clinics, and Others), is estimated to be valued at US$ 894.6 million in 2021, and is expected to exhibit a CAGR of 14.7% during the forecast period (2026-2033).

Increasing product launches by market players is anticipated to drive growth of the U.S. vasopressin market over the forecast period. For instance, in May 2020, Dr. Reddy's Laboratories announced the launch of Desmopressin Acetate Injection USP, 4 mcg/mL in the U.S. market. Moreover, Dr. Reddy’s Desmopressin Acetate Injection USP, 4 mcg/mL is available in a carton of ten 1 mL single dose ampules.

To know the latest trends and insights prevalent in the U.S. Vasopressin Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/us-vasopressin-market-4985

Market players are focusing on various inorganic strategies such as collaborations and agreements, which is anticipated to boost the U.S. Vasopressin market growth over the forecast period. For instance, in November 2021, Endo International plc, an Ireland-based pharmaceutical company, announced collaboration of its Par Sterile Products business with Premier, a U.S.-based pharmacy solutions provider, to supply its vasopressin injection, Vasostrict USP (vials) to healthcare providers in the U.S. to help maintain critical care needed during the COVID-19 pandemic.

Key Takeaways of the U.S. Vasopressin Market

The U.S. vasopressin market is expected to exhibit a CAGR of 14.7% over the forecast period (2026-2033). Growing prevalence of the cardiovascular diseases such as heart attack, coronary artery disease, and others is expected to drive growth of the U.S. vasopressin market over the forecast period. For instance, according to the American College of Cardiology Foundation, in 2019, there were approximately 1.05 million people suffering from coronary diseases in the U.S.
Based on type, the intravenous injection segment is estimated to account for 65% of the U.S. vasopressin market in 2026. A 2026 U.S. prescribing label identifies vasopressin as an intravenous injection that must be diluted and administered through continuous infusion, particularly for critically ill patients requiring rapid blood-pressure stabilization.
Based on application, the vasodilatory shock segment is expected to lead the U.S. vasopressin market with a 55% share in 2026. The current U.S. prescribing information specifically indicates vasopressin for adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Furthermore, the 2026 Surviving Sepsis Campaign recommends adding vasopressin when norepinephrine requirements escalate in septic shock.
Based on end user, the hospitals segment is projected to capture 70% of the U.S. vasopressin market in 2026. Vasopressin requires continuous intravenous infusion, blood-pressure monitoring and dose titration, making hospital emergency departments, operating rooms and intensive care units the principal treatment settings. The 2026 Surviving Sepsis Campaign also recommends ICU admission within six hours for patients requiring intensive sepsis or septic-shock management.
Some of the major players operating in the U.S. vasopressin market include Par Pharmaceutical, Pfizer Inc., Eagle Pharmaceuticals, Inc., Astellas Pharma Inc., Cumberland Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Athenex, Inc., Otsuka Holdings Co., Ltd, and Azevan Pharmaceuticals, Inc.

Key Development

On February 25, 2026, Eton Pharmaceuticals, Inc., pharmaceutical company announced U.S. FDA approval of DESMODA, the first approved oral liquid formulation of desmopressin, for managing central diabetes insipidus in adults and children. The ready-to-use solution enables precise, individualized dosing without tablet splitting, crushing, mixing, or refrigeration. Eton plans a March 9 commercial launch and estimates potential annual peak sales of USD 30–50 million, supported by patent protection through 2044 in the United States. (Source: Eton Pharmaceuticals, Inc.)
On May 6, 2026, the U.S. FDA approved Sandoz’s abbreviated new drug application for Vasopressin Injection USP, 200 units/10 mL, in a multiple-dose vial. The agency determined the product to be bioequivalent and therapeutically equivalent to Vasostrict and confirmed Sandoz’s eligibility for 180 days of generic exclusivity. The approval expands competition in the U.S. critical-care vasopressin market and could improve hospital access to lower-cost treatment for vasodilatory shock patients nationwide. (Source: U.S.FDA)
In July 2026, the U.S.FDA determined that Vasopressin in Sodium Chloride 0.9% Injection, 50 units/50 mL, had not been withdrawn for safety or effectiveness reasons. This decision enables the agency to approve qualifying ANDAs referencing the ready-to-administer formulation, creating opportunities for new premixed generic products and stronger competition in hospital and intensive-care procurement.